title: Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis.
abstract: Signs or symptoms of impaired autonomic regulation of circulation often attend Parkinson disease (PD). This review covers biomarkers and mechanisms of autonomic cardiovascular abnormalities in PD and related alpha-synucleinopathies. The clearest clinical laboratory correlate of dysautonomia in PD is loss of myocardial noradrenergic innervation, detected by cardiac sympathetic neuroimaging. About 30-40% of PD patients have orthostatic hypotension (OH), defined as a persistent, consistent fall in systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within 3 min of change in position from supine to standing. Neuroimaging evidence of cardiac sympathetic denervation is universal in PD with OH (PD+OH). In PD without OH about half the patients have diffuse left ventricular myocardial sympathetic denervation, a substantial minority have partial denervation confined to the inferolateral or apical walls, and a small number have normal innervation. Among patients with partial denervation the neuronal loss invariably progresses over time, and in those with normal innervation at least some loss eventually becomes evident. Thus, cardiac sympathetic denervation in PD occurs independently of the movement disorder. PD+OH also entails extra-cardiac noradrenergic denervation, but this is not as severe as in pure autonomic failure. PD+OH patients have failure of both the parasympathetic and sympathetic components of the arterial baroreflex. OH in PD therefore seems to reflect a "triple whammy" of cardiac and extra-cardiac noradrenergic denervation and baroreflex failure. In contrast, most patients with multiple system atrophy, which can resemble PD+OH clinically, do not have evidence for cardiac or extra-cardiac noradrenergic denervation. Catecholamines in the neuronal cytoplasm are potentially toxic, via spontaneous and enzyme-catalyzed oxidation. Normally cytoplasmic catecholamines are efficiently taken up into vesicles via the vesicular monoamine transporter. The recent finding of decreased vesicular uptake in Lewy body diseases therefore suggests a pathogenetic mechanism for loss of catecholaminergic neurons in the periphery and brain. Parkinson disease (PD) is one of the most common chronic neurodegenerative diseases of the elderly, and it is likely that as populations age PD will become even more prevalent and more of a public health burden. Severe depletion of dopaminergic neurons of the nigrostriatal system characterizes and likely produces the movement disorder (rest tremor, slowness of movement, rigid muscle tone, and postural instability) in PD. Over the past two decades, compelling evidence has accrued that PD also involves loss of noradrenergic neurons in the heart. This finding supports the view that loss of catecholaminergic neurons, both in the nigrostriatal system and the heart, is fundamental in PD. By the time PD manifests clinically, most of the nigrostriatal dopaminergic neurons are already lost. Identifying laboratory measures-biomarkers-of the disease process is therefore crucial for advances in treatment and prevention. Deposition of the protein, alpha-synuclein, in the form of Lewy bodies in catecholaminergic neurons is a pathologic hallmark of PD. Alpha-synucleinopathy in autonomic neurons may occur early in the pathogenetic process. The timing of cardiac noradrenergic denervation in PD is therefore a key issue. This review updates the field of autonomic cardiovascular abnormalities in PD and related disorders, with emphasis on relationships among striatal dopamine depletion, sympathetic noradrenergic denervation, and alpha-synucleinopathy.
authors.affiliation: Department of Neurology, University of Pittsburgh Medical Center, 3471 Fifth Ave, Suite 811, Kaufmann Medical Building, Pittsburgh, PA 15213-3232, USA. jains@upmc.edu
authors.forename: Samay
authors.initials: S
authors.lastname: Jain
authors.forename: David S
authors.initials: DS
authors.lastname: Goldstein
mesh_terms: D001341:Autonomic Nervous System / Q000503:physiopathology; D015415:Biomarkers; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D002395:Catecholamines / Q000378:metabolism; D003342:Corpus Striatum / Q000502:physiology; D003937:Diagnosis, Differential; D004298:Dopamine / Q000502:physiology; D006801:Humans; D010300:Parkinson Disease / Q000150:complications* / Q000473:pathology / Q000503:physiopathology; D054969:Primary Dysautonomias / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D013562:Sympathectomy
chemical_list: D015415:Biomarkers; D002395:Catecholamines; D004298:Dopamine
references.citation: J Neurosci. 2009 Jun 24;29(25):8103-13
references.pmid: 19553450
references.citation: Eur J Neurol. 2011 May;18(5):703-10
references.pmid: 21073636
references.citation: Clin Auton Res. 2011 Jun;21(3):133-41
references.pmid: 21279414
references.citation: Parkinsonism Relat Disord. 2008 Dec;14(8):600-7
references.pmid: 18325818
references.citation: Cleve Clin J Med. 2009 Apr;76 Suppl 2:S51-9
references.pmid: 19376985
references.citation: Neurology. 2006 Jun 27;66(12):1850-4
references.pmid: 16801649
references.citation: Clin Auton Res. 2009 Aug;19(4):259-62
references.pmid: 19399547
references.citation: Brain Res. 2000 Jun 23;868(2):191-201
references.pmid: 10854571
references.citation: J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):776-7
references.pmid: 12438492
references.citation: J Clin Invest. 1988 Jan;81(1):213-20
references.pmid: 3335637
references.citation: Acta Neuropathol. 2007 Jan;113(1):81-6
references.pmid: 17089131
references.citation: Brain Pathol. 2005 Jan;15(1):29-34
references.pmid: 15779234
references.citation: Pharmacol Rev. 2007 Jun;59(2):125-50
references.pmid: 17379813
references.citation: Acta Neuropathol. 2008 Feb;115(2):193-203
references.pmid: 17965867
references.citation: J Neurosci Res. 2000 May 15;60(4):552-8
references.pmid: 10797558
references.citation: Cell Tissue Res. 2004 Oct;318(1):121-34
references.pmid: 15338272
references.citation: Clin Auton Res. 2006 Feb;16(1):46-54
references.pmid: 16477495
references.citation: Parkinsonism Relat Disord. 2010 May;16(4):252-5
references.pmid: 20097595
references.citation: Parkinsonism Relat Disord. 2009 Feb;15(2):122-7
references.pmid: 18514012
references.citation: Clin Auton Res. 2007 Apr;17(2):118-21
references.pmid: 17334896
references.citation: Ann Neurol. 2002 Aug;52(2):220-3
references.pmid: 12210793
references.citation: N Engl J Med. 1997 Mar 6;336(10):696-702
references.pmid: 9041100
references.citation: J Neurol Sci. 2011 Nov 15;310(1-2):118-22
references.pmid: 21529844
references.citation: Chem Res Toxicol. 2009 May;22(5):835-41
references.pmid: 19388687
references.citation: Neurology. 2003 Apr 22;60(8):1327-32
references.pmid: 12707437
references.citation: Lancet Neurol. 2003 Nov;2(11):669-76
references.pmid: 14572735
references.citation: J Neural Transm (Vienna). 2003 May;110(5):517-36
references.pmid: 12721813
references.citation: PLoS One. 2010 Dec 13;5(12):e15251
references.pmid: 21179455
references.citation: Neurology. 2002 Apr 23;58(8):1247-55
references.pmid: 11971094
references.citation: Clin Neuropharmacol. 2006 May-Jun;29(3):97-105
references.pmid: 16772807
references.citation: Neuroscience. 1994 Nov;63(1):1-5
references.pmid: 7898642
references.citation: J Neurosci Res. 2004 Feb 1;75(3):429-35
references.pmid: 14743456
references.citation: Eur J Clin Invest. 1990 Dec;20(6):613-9
references.pmid: 1964123
references.citation: Hypertension. 2005 Dec;46(6):1333-9
references.pmid: 16216982
references.citation: Clin Auton Res. 2009 Jun;19(3):137-48
references.pmid: 19266158
references.citation: Arch Neurol. 2007 Mar;64(3):381-6
references.pmid: 17353381
references.citation: Clin Auton Res. 2000 Oct;10(5):285-91
references.pmid: 11198484
references.citation: Parkinsonism Relat Disord. 2011 Dec;17(10):724-9
references.pmid: 21571570
references.citation: J Clin Invest. 2011 Aug;121(8):3320-30
references.pmid: 21785221
references.citation: Clin Auton Res. 2012 Feb;22(1):57-61
references.pmid: 21796351
references.citation: Neurology. 2010 Jan 19;74(3):245-51
references.pmid: 20083801
references.citation: Circulation. 2003 Aug 12;108(6):724-8
references.pmid: 12885750
references.citation: Lancet. 1976 Nov 27;2(7996):1164-7
references.pmid: 62995
references.citation: Circulation. 2000 Jun 13;101(23):2710-5
references.pmid: 10851208
references.citation: Neurology. 1981 Jan;31(1):1-7
references.pmid: 7192816
references.citation: N Engl J Med. 2000 Sep 21;343(12):847-55
references.pmid: 10995864
references.citation: Neurology. 2003 Mar 25;60(6):1036-9
references.pmid: 12654979
references.citation: Clin Neuropharmacol. 1993 Feb;16(1):70-6
references.pmid: 8422659
references.citation: Clin Auton Res. 2002 Aug;12(4):281-5
references.pmid: 12357282
references.citation: J Neurosci. 2007 Jul 25;27(30):8138-48
references.pmid: 17652604
references.citation: Neuron. 2009 Apr 30;62(2):218-29
references.pmid: 19409267
references.citation: Circulation. 2009 Jan 6;119(1):139-46
references.pmid: 19124673